132684Oral Agonists of GPR142, an Innovative New Target for the Treatment of Type 2 DiabetesClosedFeasibility StudiesInnovate UKType-2 diabetes (T2D) affects over 420 million people worldwide, creating an enormous healthcare and socio-economic burden. The GPR142 receptor has been recently reported to be an exciting new target for the treatment of T2D with several advantages. Firstly, its activation results in insulin secretion but only in the presence of high blood sugar levels, avoiding the life-threatening side effect of low blood sugar associated with insulin-based therapies. Secondly, GPR142-based medicines would be orally administered, avoiding compliance issues caused by injectable therapies. Additionally, activating GPR142 leads to the release of GLP-1 - a clinically validated mechanism for the treatment of T2D. By applying its proprietary NMR-based approach to drug discovery, C4X Discovery has identified hit molecules for GPR142. This project is scoped to characterise and develop these hits to enable a chemical optimisation programme aiming to ultimately lead to a new, convenient, safe and effective class of T2D medicine that would have an enormous positive impact on long-term patient health and reduce the economic burden associated with the disease.